8-K: Cryoport Sells CRYOPDP to DHL, Forms Strategic Partnership

Cryoport divests its global specialty courier business, CRYOPDP, to DHL for approximately $138 million in cash plus repayment of intercompany loans, while also forming a strategic partnership to enhance supply chain solutions for the life sciences sector.

Summary

• Cryoport, Inc. has entered into a Sale and Purchase Agreement with DHL Supply Chain International Holding B.V. to sell its global specialty courier business (CRYOPDP).
• DHL will acquire 100% of the capital stock and voting rights of entities conducting business under the trade name CryoPDP.
• The transaction involves a cash payment of approximately $138 million for CryoPDP, subject to adjustments, and the repayment of intercompany loans estimated at $67 million.
• The total enterprise value of the deal is $195 million.
• The transaction is expected to close in the second or third quarter of 2025, pending regulatory approvals.
• Cryoport and DHL will also enter into a master partnership agreement to provide their respective services to each other's customers.
• For three years post-closing, Cryoport will not engage in a competitive business or hire employees of the divested business, subject to certain exceptions.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic sale of CRYOPDP to DHL, the formation of a partnership, and the expected benefits for both companies. The transaction is presented as a win-win situation, with DHL expanding its capabilities and Cryoport focusing on its core business.

Positives

• Cryoport will receive a significant cash infusion of approximately $138 million plus the repayment of intercompany loans.
• The strategic partnership with DHL is expected to expand Cryoport's reach into global growth markets like Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).
• Cryoport can focus on its core business after the divestiture.
• DHL will benefit from CRYOPDP's expertise in specialty courier services and its established operations in 15 countries.
• DHL expects cost savings and improved service levels by leveraging DHL Express and DHL Global Forwarding air capabilities.

Negatives

• Cryoport will lose the revenue stream from its CRYOPDP business.
• Cryoport is subject to a three-year non-compete agreement, restricting its ability to operate in the global freight forwarding and specialty courier services market.
• Cryoport is restricted from hiring employees of the divested business for three years.

Risks

• The transaction is subject to customary closing conditions, including regulatory approval, which could delay or prevent the deal from closing.
• Disruptions resulting from the transaction may adversely affect Cryoport's businesses and business relationships.
• Delays in satisfying closing conditions could impact the expected timeline for the transaction.
• Global credit and financial market disruptions could negatively impact the completion of the transaction.
• The success of the strategic partnership depends on the ability of Cryoport and DHL to effectively collaborate and integrate their services.

Future Outlook

Cryoport expects future benefits from the sale of CRYOPDP and the strategic collaboration with DHL, including potential impact on future revenue and revenue streams; DHL aims to expand its Pharma Specialized Network and become a leader in providing comprehensive solutions for the pharma industry.

Management Comments

• Oscar de Bok, CEO of DHL Supply Chain, stated, 'The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities'.
• Jerrell Shelton, CEO of Cryoport, commented 'We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies and patients critical supply chain needs. This strategic partnership taps into the strong expertise of DHLs Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).'

Industry Context

The acquisition reflects the increasing importance of specialized logistics in the life sciences and healthcare sector, particularly for clinical trials, biopharma, and cell & gene therapies; DHL's move to acquire CRYOPDP and partner with Cryoport positions it to capitalize on the growing demand for temperature-controlled and specialized supply chain solutions in this market.

Comparison to Industry Standards

• The enterprise value of $195 million suggests a valuation multiple based on CRYOPDP's revenue or EBITDA, which would need to be compared to similar transactions in the logistics and healthcare sectors to assess its relative value.
• Comparable companies in the specialty courier and logistics space include FedEx, UPS, and World Courier, which also offer specialized services for the life sciences industry.
• The strategic partnership between DHL and Cryoport is similar to other collaborations in the industry aimed at providing end-to-end supply chain solutions for pharmaceutical and biotechnology companies.
• The three-year non-compete agreement is a standard provision in M&A transactions to protect the buyer's investment and prevent the seller from immediately competing with the acquired business.

Stakeholder Impact

• Shareholders: Positive impact due to the cash infusion and strategic partnership.
• Employees: Potential impact on CRYOPDP employees as they transition to DHL; Cryoport employees may see new opportunities in the core business.
• Customers: Enhanced supply chain solutions and expanded global reach.
• Suppliers: Potential changes in relationships as CRYOPDP integrates with DHL.
• Creditors: Improved financial stability for Cryoport due to the cash infusion.

Next Steps

• Obtain regulatory approvals for the transaction.
• Finalize the terms of the master partnership agreement between Cryoport and DHL.
• Complete the operational transition of CRYOPDP to DHL.
• Cryoport to host an investor call on March 31, 2025, to discuss the transaction.

Key Dates

Keywords

Cryoport, DHL, CRYOPDP, acquisition, strategic partnership, specialty courier, life sciences, supply chain, divestiture, regulatory approval